Chan ATC - Search Results

1

Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.

Tang SQ, Chen L, Li WF, Chan ATC, Huang SH, Chua MLK, O'Sullivan B, Lee AWM, Lee NY, Zhang Y, Chen YP, Xu C, Sun Y, Tang LL, Ma J. Tang SQ, et al. Among authors: chan atc. Radiother Oncol. 2022 Feb;167:179-186. doi: 10.1016/j.radonc.2021.12.029. Epub 2021 Dec 28. Radiother Oncol. 2022. PMID: 34971660 Clinical Trial.

2

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Chan AT, et al. J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9. doi: 10.1093/jnci/94.21.1614. J Natl Cancer Inst. 2002. PMID: 12419787

3

Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients.

Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM. Chan KC, et al. Cancer Res. 2003 May 1;63(9):2028-32. Cancer Res. 2003. PMID: 12727814

4

Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.

Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM. Leung SF, et al. Cancer. 2003 Jul 15;98(2):288-91. doi: 10.1002/cncr.11496. Cancer. 2003. PMID: 12872347 Free article.

5

Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma.

To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT, Johnson PJ, Lo YM. To EW, et al. Clin Cancer Res. 2003 Aug 15;9(9):3254-9. Clin Cancer Res. 2003. PMID: 12960110

6

A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma.

Hui EP, Poon TC, Teo PM, Mo F, Zee B, Leung SF, Ho S, Mok TS, Kwan WH, Johnson PJ, Chan AT. Hui EP, et al. Radiother Oncol. 2003 Oct;69(1):53-62. doi: 10.1016/s0167-8140(03)00248-2. Radiother Oncol. 2003. PMID: 14597357

7

Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas.

Yu KH, Lo YM, Tse GM, Chan KC, Chan AB, Chow KC, Ma TK, Vlantis AC, Leung SF, van Hasselt CA, Johnson PJ, Chan AT. Yu KH, et al. Clin Cancer Res. 2004 Mar 1;10(5):1726-32. doi: 10.1158/1078-0432.ccr-0991-3. Clin Cancer Res. 2004. PMID: 15014025

8

Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.

Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, Mok TS, Kam M, Chan LS, Chiu SK, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PM, Zee B. Chan AT, et al. J Clin Oncol. 2004 Aug 1;22(15):3053-60. doi: 10.1200/JCO.2004.05.178. J Clin Oncol. 2004. PMID: 15284255 Clinical Trial.

9

Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods.

Teo PM, Ma BB, Chan AT. Teo PM, et al. Radiother Oncol. 2004 Nov;73(2):163-72. doi: 10.1016/j.radonc.2004.06.005. Radiother Oncol. 2004. PMID: 15542163 Review.

10

Pathogenesis and treatment of nasopharyngeal carcinoma.

Chan AT, Teo PM, Huang DP. Chan AT, et al. Semin Oncol. 2004 Dec;31(6):794-801. doi: 10.1053/j.seminoncol.2004.09.008. Semin Oncol. 2004. PMID: 15599857 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page